Sakai R, et al. - Researchers assessed the risks of herpes zoster (HZ) in tumour necrosis factor inhibitor (TNFI) and non-TNFI users with rheumatoid arthritis (RA) over 3 years in Japan. A nested case-control study (NCC) was conducted in the RA group to evaluate the risks of HZ in TNFI and non-TNFI users. Experts noted a significant association of rheumatoid arthritis with the development of HZ. They identified the use of corticosteroids ≥ 5 mg/day as a significant risk factor, whereas either TNFI or non-TNFI use were not.